Systemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in rats

Basit Öğe Kaydı
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridKaradag, Cetin Hakan/0000-0002-4763-986X
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidKaradag, Cetin Hakan/H-4899-2013
dc.contributor.authorKaradag, HC
dc.contributor.authorUlugol, A
dc.contributor.authorTamer, M
dc.contributor.authorIpci, Y
dc.contributor.authorDokmeci, I
dc.date.accessioned2024-06-12T11:09:11Z
dc.date.available2024-06-12T11:09:11Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractRecent evidence suggests that agmatine, an endogenous polyamine metabolite, might be an important neurotransmitter in central nervous system and has potential as a treatment of pain. The aim of our study was to evaluate the effect of agmatine on allodynia in two experimental neuropathic pain models, the spinal nerve ligation (SNL) model and the streptozocin (STZ)-induced diabetic neuropathy in rats, and to determine if the N-methyl-D-aspartate (NMDA) receptor antagonists and the nitric oxide synthase (NOS) inhibitors influence this effect of agmatine. Nerve injury was produced by tight ligation of the left L5 and L6 spinal nerves, and diabetic neuropathy is induced with the injection of a single dose of STZ; these procedures resulted in tactile allodynia in the hindpaw. Tactile allodynia was detected by application of von Frey filaments to the plantar surface of the foot. Agmatine reduced mechanical allodynia with its higher doses. Dizocilpine maleate (MK-801), a NMDA receptor antagonist, and the NOS inhibitors, N-G-nitro-L-arginine methyl ester and 7-nitroindazole, did not influence the antiallodynic effect of agmatine. These results suggest that agmatine has an antiallodynic effect in both spinal nerve ligation and diabetic models and may be a promising drug in the treatment of neuropathic pain. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/S0304-3940(02)01456-8
dc.identifier.endpage90en_US
dc.identifier.issn0304-3940
dc.identifier.issn1872-7972
dc.identifier.issue1en_US
dc.identifier.pmid12618307en_US
dc.identifier.scopus2-s2.0-0037435382en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage88en_US
dc.identifier.urihttps://doi.org/10.1016/S0304-3940(02)01456-8
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22702
dc.identifier.volume339en_US
dc.identifier.wosWOS:000181411500022en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofNeuroscience Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeuropathyen_US
dc.subjectPainen_US
dc.subjectAllodyniaen_US
dc.subjectAgmatineen_US
dc.subjectDiabetesen_US
dc.subjectSpinal Nerve Ligationen_US
dc.subjectNerve Ligationen_US
dc.subjectAmitriptylineen_US
dc.subjectMorphineen_US
dc.titleSystemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu